Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 1/20 | 1.00 |
| ▸ | ICAM1 | P05362 | 1/20 | 1.00 |
| ▸ | ITGAL | P20701 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.85 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.85 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.85 |
| ▸ | HTR1A | P08908 | 5/20 | 0.85 |
| ▸ | DRD2 | P14416 | 4/20 | 0.85 |
| ▸ | LMNA | P02545 | 4/20 | 0.85 |
| ▸ | MAPT | P10636 | 4/20 | 0.85 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.85 |
| ▸ | TP53 | P04637 | 4/20 | 0.85 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.85 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.85 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.85 |
| ▸ | DRD1 | P21728 | 4/20 | 0.85 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.85 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.85 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.85 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cholrphenethazine SCHEMBL29376339 | 0.99 | ITGB2 (0.97) | ITGB2ICAM1ITGALCYP1A2CYP2D6 | |
| Cholrphenethazine SCHEMBL9724481 | 0.99 | ITGB2 (0.97) | ITGB2ICAM1ITGALCYP1A2CYP2D6 | |
| Chlorpromazine SCHEMBL29358018 | 0.92 | CYP1A2 (1.00) | ITGB2ICAM1ITGALCYP1A2CYP2D6 | |
| Chlorpromazine SCHEMBL29367385 | 0.92 | CYP1A2 (1.00) | ITGB2ICAM1ITGALCYP1A2CYP2D6 | |
| Chlorpromazine SCHEMBL8321 | 0.92 | CYP1A2 (1.00) | ITGB2ICAM1ITGALCYP1A2CYP2D6 | |
| Chlorpromazine SCHEMBL23326209 | 0.91 | CYP1A2 (1.00) | ITGB2ICAM1ITGALCYP1A2CYP2D6 | |
| Chlorpromazine SCHEMBL5483904 | 0.91 | CYP1A2 (1.00) | ITGB2ICAM1ITGALCYP1A2CYP2D6 | |
| Chlorpromazine SCHEMBL41771 | 0.91 | CYP1A2 (1.00) | ITGB2ICAM1ITGALCYP1A2CYP2D6 | |
| SCHEMBL9724480 | 0.91 | CYP1A2 (0.93) | ITGB2ICAM1ITGALCYP1A2CYP2D6 | |
| Chlorpromazine SCHEMBL29351728 | 0.91 | CYP1A2 (1.00) | ITGB2ICAM1ITGALCYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1976723-A | Treatment of infectious diseases | BKG PHARMA APS (DK) | 2007-06-06 | — | — | CN | claimed |
| EP-1744781-A1 | TREATMENT OF INFECTIOUS DISEASES | Bkg Pharma Aps (DK) | 2007-01-24 | — | — | EP | claimed |
| WO-2005105145-A1 | TREATMENT OF INFECTIOUS DISEASES | BKG PHARMA APS (DK) | 2005-11-10 | — | — | WO | claimed |
| EP-1744781-B1 | TREATMENT OF INFECTIOUS DISEASES | BKG PHARMA APS (DK) | 2012-07-04 | — | — | EP | disclosed |
| CN-1976723-B | Use of preparing medicine for treating or preventing infectious diseases | BKG PHARMA APS | 2010-12-29 | — | — | CN | disclosed |
| EP-2260870-A2 | Treatment of infectious diseases with combinations of a thioxanthene derivative with an anti-infective agent | BKG Pharma ApS (DK) | 2010-12-15 | — | — | EP | disclosed |
| US-20080318970-A1 | Treatment of Infectious Diseases | BKG PHARMA APS (DK) | 2008-12-25 | — | — | US | disclosed |
| CN-1976723-A | Treatment of infectious diseases | BKG PHARMA APS (DK) | 2007-06-06 | — | — | CN | disclosed |
| EP-1744781-A1 | TREATMENT OF INFECTIOUS DISEASES | Bkg Pharma Aps (DK) | 2007-01-24 | — | — | EP | disclosed |
| WO-2005105145-A1 | TREATMENT OF INFECTIOUS DISEASES | BKG PHARMA APS (DK) | 2005-11-10 | — | — | WO | disclosed |
| US-5104858-A | Administering trans-flupenthiyol with doxorubicin; lack of antipsychotic activity reduces side effects | YALE UNIVERSITY (US) | 1992-04-14 | — | — | US | disclosed |
| EP-0361485-A2 | A method of sensitizing multidrug resistant cells to antitumor agents | YALE UNIVERSITY (US) | 1990-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318970-A1 | Treatment of Infectious Diseases | ABCC1, TST, TPMT | ITGB2 4165/4885ICAM1 931/4885ITGAL 3376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.